在投资者对Hemostemix实验疗法的兴趣增加的情况下,Hemostemix的股份大宗猛增29%。 Hemostemix shares surged 29% on heavy volume amid rising investor interest in its experimental therapies.

Hemostemix (CVE:HEM) 的股份在星期五跳跃了29.4%, 在511%的交易量猛增至602,760股时达到0.11科多巴元。 Hemostemix (CVE:HEM) shares jumped 29.4% on Friday, reaching C$0.11 amid a 511% surge in trading volume to 602,760 shares. 加拿大临床阶段生物技术开发了用于血管疾病的ACP-01干细胞疗法和用于神经病痛的NCP-01干细胞疗法,其市场上限上升到2 073万开曼元。 The clinical-stage Canadian biotech, developing stem cell therapies ACP-01 for vascular diseases and NCP-01 for neuropathic pain, saw its market cap rise to C$20.73 million. 股市最近的集市反映了投资者的强烈兴趣,尽管股市的P/E比率是负的,波动性很大,正如1.25贝塔所示,股市仍然无利可图。 The stock’s recent rally reflects strong investor interest, though it remains unprofitable with a negative P/E ratio and high volatility, as indicated by a beta of 1.25.